# OnCo record nct07207070 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07207070/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07207070", "NCT07207070" ;
  schema:name "A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer"@en ;
  schema:description "A phase 3 trial testing JS105 in HR-positive / HER2-negative breast cancer, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07207070/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07207070> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2025-11-12" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:drugs <https://onco.cc/drugs/js105/> ;
  onco:companies <https://onco.cc/companies/junshi/> .